文献速递心脑血管急症重症综合管理与镇静镇痛

急性血管性脑损伤患者的发热预防:INTREPID随机临床试验

Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论急性血管性脑损伤患者使用自动体表控温装置预防性维持正常体温可降低发热负荷,但未改善3个月功能结局。

INTREPID为开放标签、结局盲法评估的随机临床试验,纳入686例计划中的危重卒中患者,来自7个国家43个ICU,2017年3月至2021年4月入组。发热预防组(n=339)使用自动体表控温装置目标37.0°C持续14天或至ICU出院;标准治疗组(n=338)在体温≥38°C时按标准化分层方案处理。主要终点每日平均发热负荷在发热预防组显著低于标准治疗组(0.37 vs 0.73 °C-hour,差值-0.35,95%CI -0.51至-0.20,P<.001)。3个月功能恢复(改良Rankin量表移位分析)无显著差异(OR 1.09,95%CI 0.81至1.46,P=.54)。因计划中期分析显示主要次要终点无效而提前终止入组。

要点

  • 发热预防组每日平均发热负荷0.37 °C-hour,标准治疗组0.73 °C-hour,差值-0.35(95%CI -0.51至-0.20),P<.001。
  • 3个月改良Rankin量表移位分析无显著差异:中位mRS 4.0 vs 4.0,OR 1.09(95%CI 0.81至1.46),P=.54。
  • 发热负荷组间差异按卒中亚型:缺血性卒中-0.10(95%CI -0.35至0.15),脑出血-0.50(95%CI -0.78至-0.22),蛛网膜下腔出血-0.52(95%CI -0.81至-0.23),均P<.001(Wilcoxon秩和检验)。
  • 主要不良事件发生率发热预防组82.2% vs 标准治疗组75.9%,其中感染33.8% vs 34.5%,心脏疾病14.5% vs 14.0%,呼吸系统疾病24.5% vs 20.5%。
  • 因计划中期分析显示主要次要终点无效,入组提前终止。

适用人群与场景

  • 危重卒中患者,包括缺血性卒中254例、脑出血223例、蛛网膜下腔出血200例;女性345例(51%),中位年龄62岁。
  • 来自7个国家43个重症监护病房,2017年3月至2021年4月入组。

处置流程与药物剂量

  • 发热预防组(n=339):使用自动体表控温装置,目标体温37.0°C,持续14天或至ICU出院。
  • 标准治疗组(n=338):体温≥38°C时按标准化分层方案处理发热。

研究设计与关键结果

  • 研究类型:开放标签随机临床试验,结局盲法评估;计划入组1176例,实际入组686例,9例同意但未随机,主要分析人群677例;433例(64%)完成12个月随访。
  • 主要终点每日平均发热负荷:发热预防组0.37(SD 1.0)°C-hour(范围0.0-8.0)vs 标准治疗组0.73(SD 1.1)°C-hour(范围0.0-10.3),差值-0.35(95%CI -0.51至-0.20),P<.001。
  • 主要终点按卒中亚型组间差异:缺血性卒中-0.10(95%CI -0.35至0.15),脑出血-0.50(95%CI -0.78至-0.22),蛛网膜下腔出血-0.52(95%CI -0.81至-0.23),均P<.001(Wilcoxon秩和检验)。
  • 主要次要终点3个月功能恢复(6分类改良Rankin量表移位分析,评分0无症状至6死亡):中位mRS 4.0 vs 4.0,有利移位OR 1.09(95%CI 0.81至1.46),P=.54,无显著差异。
  • 主要不良事件(死亡、肺炎、脓毒症、恶性脑水肿):发热预防组82.2% vs 标准治疗组75.9%;感染33.8% vs 34.5%,心脏疾病14.5% vs 14.0%,呼吸系统疾病24.5% vs 20.5%。
  • 因计划中期分析显示主要次要终点无效,入组提前终止。

证据类型、等级与局限

  • 证据类型:随机临床试验(开放标签、结局盲法评估)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在急性血管性脑损伤危重患者中,使用自动体表控温装置预防性维持正常体温可降低发热负荷,但未改善3个月功能结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Fever is associated with worse outcomes in patients with stroke, but whether preventing fever improves outcomes is unclear.

OBJECTIVE: To determine whether fever prevention after acute vascular brain injury is achievable and impacts functional outcome.

DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial with blinded outcome assessment that enrolled 686 of 1176 planned critically ill patients with stroke at 43 intensive care units in 7 countries from March 2017 to April 2021 (last date of follow-up was May 12, 2022).

INTERVENTION: Patients randomized to fever prevention (n = 339) were targeted to 37.0 °C for 14 days or intensive care unit discharge using an automated surface temperature management device. Standard care patients (n = 338) received standardized tiered fever treatment on occurrence of temperature of 38 °C or greater.

MAIN OUTCOMES AND MEASURES: Primary outcome was daily mean fever burden: the area under the temperature curve above 37.9 °C (total fever burden) divided by the total number of hours in the acute phase, multiplied by 24 hours (°C-hour). The principal secondary outcome was 3-month functional recovery by shift analysis of the 6-category modified Rankin Scale, which is scored from 0 (no symptoms) to 6 (death). Major adverse events included death, pneumonia, sepsis, and malignant cerebral edema.

RESULTS: Enrollment was stopped after a planned interim analysis demonstrated futility of the principal secondary end point. In total, 686 patients were enrolled, and 9 were consented but not randomized, leaving a primary analysis population of 677 patients (254 ischemic stroke, 223 intracerebral hemorrhage, 200 subarachnoid hemorrhage; 345 were female [51%]; median age, 62 years) with 433 (64%) completing the study through 12 months. Daily mean (SD) fever burden was significantly lower in the fever prevention group (0.37 [1.0] °C-hour; range, 0.0-8.0 °C-hour) compared with the standard care group (0.73 [1.1] °C-hour; range, 0.0-10.3 °C-hour) (difference, -0.35 [95% CI, -0.51 to -0.20]; P < .001). Between-group differences for the primary outcome by stroke subtype were -0.10 (95% CI, -0.35 to 0.15) for ischemic stroke, -0.50 (95% CI, -0.78 to -0.22) for intracerebral hemorrhage, and -0.52 (95% CI, -0.81 to -0.23) for subarachnoid hemorrhage (all P < .001 by Wilcoxon rank-sum test). There was no significant difference in functional recovery at 3 months (median modified Rankin Scale score, 4.0 vs 4.0, respectively; odds ratio for a favorable shift in functional outcome, 1.09 [95% CI, 0.81 to 1.46]; P = .54). Major adverse events occurred in 82.2% of participants in the fever prevention group vs 75.9% in the standard care group, including 33.8% vs 34.5% for infections, 14.5% vs 14.0% for cardiac disorders, and 24.5% vs 20.5% for respiratory disorders.

CONCLUSIONS AND RELEVANCE: In patients with acute vascular brain injury, preventive normothermia using an automated surface temperature management device effectively reduced fever burden but did not improve functional outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02996266.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Greer DM, Helbok R, Badjatia N, et al. Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial. JAMA. 2024. PMID: 39320879. doi:10.1001/jama.2024.14745

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。